RESUMO
This study introduces the current status of the coronavirus disease 2019 （COVID-19） epidemic， the adjustment of response initiatives， and the global variation of novel coronaviruses and vaccination in Europe， the United States， Japan， and Singapore. It summarizes the achievements in prevention and control efforts in China during COVID-19 epidemic. In addition， it describes the key public health issues in Chinese response strategy that includes： promoting the establishment of a population immunization system； optimizing health certification by unifying health codes， trip codes， and vaccine passes as a triple-identification at the national level； retaining nucleic acid testing as a technical means of detecting the source of infection and epidemiological investigation of close contacts； adhering to the requirements of public places， public transportation and other measures such as wearing masks； strengthening the surveillance of COVID-19 and respiratory infectious diseases； normalizing the timing of implementation of prevention and control strategies.
RESUMO
This study introduces the current status of the coronavirus disease 2019 （COVID-19） epidemic， the adjustment of response initiatives， and the global variation of novel coronaviruses and vaccination in Europe， the United States， Japan， and Singapore. It summarizes the achievements in prevention and control efforts in China during COVID-19 epidemic. In addition， it describes the key public health issues in Chinese response strategy that includes： promoting the establishment of a population immunization system； optimizing health certification by unifying health codes， trip codes， and vaccine passes as a triple-identification at the national level； retaining nucleic acid testing as a technical means of detecting the source of infection and epidemiological investigation of close contacts； adhering to the requirements of public places， public transportation and other measures such as wearing masks； strengthening the surveillance of COVID-19 and respiratory infectious diseases； normalizing the timing of implementation of prevention and control strategies.
RESUMO
To study the pharmacokinetics of puerarin in compound Longmaining(FFLMN) in normal rats and myocardial ischemia rats, and investigate its correlation with anti-myocardial ischemia effect of FFLMN. Models of myocardial ischemia rats were produced by subcutaneous injection of isoproterenol(ISO), then FFLMN extract solution was administered by gavage. Orbital sinus blood sampling was collected at different time points after gavage. HPLC-UV method was applied to determine the concentration of puerarin in plasma, and compare the difference in pharmacokinetics between normal rats and model rats after application of same dose of FFLMN. Meanwhile, microplate reader was used to determine IL-6 and SOD activities in plasma of different time points, and draw dose-effect curve. The results indicated that the pharmacokinetics of puerarin conformed to the two-compartment model in both normal group and myocardial ischemia model group. In the comparison of main pharmacokinetic parameters between two groups: AUC0-∞=(11.451±3.228) mg•h•L⁻¹,AUC0-t=(14.047±3.765) mg•h•L⁻¹, Cmax=(5.623±1.40) mg•L⁻¹ in normal group; AUC0-∞=(68.849±50.396 9) mg•h•L⁻¹, AUC0-t= (58.312±45.802) mg•h•L⁻¹,Cmax=(18.456±7.517) mg•L⁻¹ in treatment group. The SOD level was significantly increased and IL-6 concentration was significantly decreased in plasma, indicating that as compared with the normal group, puerarin in FFLMN had a higher plasma concentration, slower elimination rate and higher bioavailability. Therefore, puerarin concentration in plasma has correlation with the anti-myocardial ischemia effect of FFLMN, which could increase SOD level and inhibit the release of IL-6.